BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-265@pharmaconomics
DTSTAMP:20260707T014340Z
DTSTART;VALUE=DATE:20260209
DTEND;VALUE=DATE:20260210
SUMMARY:BFRI Phase 3 — Ameluz
DESCRIPTION:Phase 3 trial results for Ameluz in mild to moderate actinic keratoses (AKs) are due Feb 9\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1858685/000149315226005717/ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/265
URL:https://pharmaconomics.com/e/265
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BFRI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR